P/E ratio for EyePoint Pharmaceuticals (EYPT)
P/E ratio as of May 2024 (TTM): -7.50
According to EyePoint Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.49624. At the end of 2022 the company had a P/E ratio of -1.28.
P/E ratio history for EyePoint Pharmaceuticals from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.28 | -78.84% |
| 2021 | -6.06 | 226.91% |
| 2020 | -1.85 | -33.03% |
| 2019 | -2.77 | 94.78% |
| 2018 | -1.42 | -22.37% |
| 2017 | -1.83 | -40.91% |
| 2016 | -3.10 | -55.65% |
| 2015 | -6.99 | -157.79% |
| 2014 | 12.1 | -270.51% |
| 2013 | -7.09 | 169.51% |
| 2012 | -2.63 | 160.67% |
| 2011 | -1.01 | -104.94% |
| 2010 | 20.4 | -185.4% |
| 2009 | -23.9 | 9069.59% |
| 2008 | -0.2610 | -91.82% |
| 2007 | -3.19 | 1591.21% |
| 2006 | -0.1886 | -98.91% |
| 2005 | -17.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | -55.53% | Bahamas |
 NRC Health
NRC | 29.4 | -492.02% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.